Table 1

Characteristics of the patients at baseline

VariablesDefinite TGCV
(n=17)
Probable TGCV
(n=22)
Non-TGCV control
(n=44)
P value
Age, years66.6±10.963.3±11.864.3±11.90.72
Male, n (%)12 (70.6)20 (90.9)33 (75.0)0.23
Height, m1.58±0.111.63±0.061.62±0.100.25
Weight, kg54.9±12.963.9±15.458.2±14.70.14
BMI, kg/m2 21.8±4.423.9±4.921.9±4.10.17
Prior myocardial infarction, n (%)1 (5.9)5 (22.7)0 (0.0)0.003
Prior CABG, n (%)1 (5.9)1 (4.5)0 (0.0)0.30
Dialysis period, years (IQR)6.0 (4.5–9.5)2.0 (1.0–6.8)5.0 (2.0–16.0)0.06
Primary causes of dialysis
 Nephrosclerosis, n (%)3 (17.6)1 (4.5)10 (22.7)<0.001
 Diabetic nephropathy, n (%)9 (52.9)20 (90.9)9 (20.5)
 Chronic glomerulonephritis, n (%)5 (29.4)0 (0.0)15 (34.1)
 Others, n (%)0 (0.0)0 (0.0)7 (15.9)
 Unknown, n (%)0 (0.0)1 (4.5)3 (6.8)
Coronary risk factor
 Hypertension, n (%)13 (76.5)19 (86.4)36 (81.8)0.73
 Dyslipidaemia, n (%)9 (52.9)11 (50.0)11 (25.0)0.047
 Diabetes, n (%)9 (52.9)22 (100.0)11 (25.0)<0.001
 IGT, n (%)1 (5.9)0 (0.0)5 (11.4)0.24
 Diabetes or IGT, n (%)10 (58.8)22 (100.0)16 (36.4)<0.001
 Current smoker, n (%)3 (17.6)6 (27.3)11 (25.0)0.77
Medications
 Insulin, n (%)7 (41.2)13 (59.1)3 (6.8)<0.001
 Statins, n (%)8 (47.1)9 (40.9)9 (20.5)0.07
 CCB, n (%)8 (47.1)15 (68.2)32 (72.7)0.16
 ACEi/ARB, n (%)5 (29.4)11 (50.0)17 (38.6)0.42
 β blocker, n (%)5 (29.4)5 (22.7)14 (31.8)0.74
 Thiazide, n (%)1 (5.9)0 (0.0)0 (0.0)0.14
Laboratory data
 CRP, mg/L (IQR)3.0 (2.0–8.0)2.0 (1.0–6.0)2.0 (1.0–5.0)0.63
 Alb, mg/dL3.9±0.63.8±0.73.7±0.40.50
 GNRI99.6±12.3101.4±12.297.0±11.50.34
 HbA1c, % (IQR)5.4 (5.1–6.6)6.3 (5.8–7.1)5.2 (4.9–5.4)<0.001
 Total cholesterol, mg/dL167±23168±26154±330.14
 LDL-cholesterol, mg/dL97±2496±2386±290.20
 HDL-cholesterol, mg/dL52±1446±1051±180.31
 TG, mg/dL (IQR)113 (75–184)101 (71–173)94 (61–138)0.64
 LVEF, %63.8±11.154.6±10.761.9±11.80.22
 WOR of BMIPP (%)−5.87±18.613.6±14.816.3±9.9<0.001
 WOR of BMIPP <10% n (%)17 (100.0)7 (31.8)11 (25.0)<0.001
Coronary morphology
 Number of significant stenosis1.5±1.11.7±1.60.4±0.8<0.001
 Diffuse narrowing, n (%)17 (100.0)15 (68.2)9 (20.5)<0.001
Invasive therapies
 PCI, n (%)14 (82.4)13 (59.1)10 (22.7)<0.001
 CABG, n (%)1 (5.9)2 (9.1)1 (2.3)0.46
 PCI or CABG, n (%)*15 (88.2)15 (68.2)11 (25.0)<0.001
  • Continuous variables were expressed as means±SD, and three-group comparisons were performed using one-way ANOVA analysis. Categorical variables were presented as patient number (%) and analysed using the χ2 test.

  • *PCI or CABG indicates the number of procedures underwent at the time of the initial diagnosis based on ischaemic chest symptoms with an ischaemic ECG change and with a positive functional ischaemia assessment and/or BMIPP findings.

  • ACEi, angiotensin conversion enzyme inhibitor; Alb, albumin; ARB, angiotensin receptor blocker; BMI, body mass index; BMIPP, β-methyl-iodophenyl-pentadecanoic acid; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; CRP, C-reactive protein; GNRI, geriatric nutritional risk index; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; TG, triglyceride; TGCV, triglyceride deposit cardiomyovasculopathy; WOR, washout rate.